For patients diagnosed with rare diseases like hemophilia and muscular dystrophy, treatment has historically been difficult and the prognoses terminal. But the advent of new cell and gene therapies are providing hope, as they fight the root cause of disease [See the full post…]

The pharmaceutical supply chain has long been ripe for disruption and who better to lead the way than Mark Cuban, a “shark” who has never shied away from a challenge. Mark launched the Mark Cuban Cost Plus Drug Company in [See the full post…]

With recent innovation and policy movement related to the pharmaceutical supply chain, are we on the verge of demonstrable change that will promote greater transparency and affordability for prescription drugs? On this episode of the Business Group on Health podcast, [See the full post…]